DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 20:08:57 11/06/2024 BST | ||
| 387.3 EUR | +0.11% |
|
| Current month | +3.36% | ||
| 1 month | +6.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 387.3 | +0.11% |
| 10/06/24 | 386.8 | +0.28% |
| 07/06/24 | 385.7 | +0.93% |
| 06/06/24 | 382.2 | -0.01% |
| 05/06/24 | 382.2 | +1.09% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 08:08 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG1BT2 |
| ISIN | DE000MG1BT28 |
| Date issued | 02/04/2024 |
| Maturity | 21/03/2025 (283 Days) |
| Parity | 1 : 1 |
| Emission price | 355.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 388 € |
|---|---|
| Lowest since issue | 345.2 € |
| Spread | 0.32 € |
| Spread % | 0.08% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483.3
USD
Average target price
463.4
USD
Spread / Average Target
-4.11%
- Stock Market
- Certificates
- Certificat
